Opthea: Small Australian Company Aiming To Upend The Wet AMD Market
Source: SeekingAlpha
2025-01-30 10:50:04 ET
Summary
- Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD, showing promising Phase 2b results.
- Wet AMD treatments like Lucentis and Eylea have limitations; sozinibercept aims to improve efficacy by targeting a broader VEGF family.
- Financially, Opthea has a market cap of $797mn and a cash runway of 4-5 quarters, but faces transparency and dilution risks.
- Despite compelling data, market entry challenges and low trading volume make me cautious; I await topline data before investing.
...
Read the full article on Seeking Alpha
For further details see:
Opthea: Small Australian Company Aiming To Upend The Wet AMD Market
Opthea Limited
NASDAQ: OPT
OPT Trading
-2.05% G/L:
$3.41 Last:
3,025 Volume:
$3.48 Open:
OPT Latest News
OPT Stock Data
$583,100,698
167,235,331
N/A
12
537820%
Biotechnology & Life Sciences
Healthcare
AU
South Yarra
